US Patent

US11873300 — Crystalline forms of CFTR modulators

Method of Use · Assigned to Vertex Pharmaceuticals Inc · Expires 2040-08-13 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent discloses crystalline forms of a compound used to treat cystic fibrosis, along with methods for making and using it.

USPTO Abstract

Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4083`	—
`U-4083`	—

Patent Metadata

Patent number: US11873300
Jurisdiction: US
Classification: Method of Use
Expires: 2040-08-13
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Vertex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.